SARS-CoV-2 Infection Alters the Phenotype and Gene Expression of Adipocytes

Quaranta, Paola; Scabia, Gaia; Storti, Barbara; Dattilo, Alessia; Quintino, Lara; Perrera, Paola; Di Primio, Cristina; Costa, Mario; Pistello, Mauro; Bizzarri, Ranieri; Maffei, Margherita

doi:10.3390/ijms25042086

Cited by 3 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…40 showing that cells transfected with virus non-structural proteins (nsp 3,4 and 6) to form RO-like structures (ROLS) also accumulate, then consume LDs during the process of ROLS formation. A recent study reported an increase in the LD area of infected Simpson-Golabi-Behmel syndrome (SGB)-derived adipocytes 42 . This might be a result of the timepoint in which this analysis was made in addition to variations in dynamics of cellular responses to infection across the hTERT and SGB-derived adipocytes.…”

Section: Discussionmentioning

confidence: 99%

FABP4 as a Therapeutic Host Target Controlling SARS-CoV2 Infection

Baazim,

Koyuncu,

Tuncman

et al. 2024

Preprint

View full text Add to dashboard Cite

Host metabolic fitness is a critical determinant of infectious disease outcomes. In COVID-19, obesity and aging are major high-risk disease modifiers, although the underlying mechanism remains unknown. Here, we demonstrate that fatty acid binding protein 4 (FABP4), a critical regulator of metabolic dysfunction in these conditions, regulates SARS-CoV2 pathogenesis. Our study revealed that elevated FABP4 levels in COVID-19 patients strongly correlate with disease severity. In adipocytes and airway epithelial cells we found that loss of FABP4 function by genetic or pharmacological means impaired SARS-CoV2 replication and disrupted the formation of viral replication organelles. Furthermore, treatment of infected hamsters with FABP4 inhibitors alleviated lung damage and fibrosis and reduced lung viral titers. These results highlight a novel host factor critical for SARS-CoV2 infection and the therapeutic potential of FABP4-targeting agents in treating COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

FABP4 as a Therapeutic Host Target Controlling SARS-CoV2 Infection

Baazim,

Koyuncu,

Tuncman

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

COVID-19 and persistent symptoms: implications for polycystic ovary syndrome and its management

Zhang,

Wu,

Mprah

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

The COVID-19 pandemic has left a profound mark on global health, leading to substantial morbidity and mortality worldwide. Beyond the immediate symptoms of infection, the emergence of “long COVID”, the long-term effects of SARS-CoV-2, has become a significant public health concern. Long COVID is a multifaceted condition affecting various organs and systems, including the cardiovascular, digestive, nervous, and endocrine systems. Individuals diagnosed with polycystic ovary syndrome (PCOS) may face an increased risk of severe COVID-19 symptoms and infection. It is crucial to comprehend how long COVID affects PCOS patients to devise effective treatment and care strategies. Here, we review the detrimental effects of COVID-19 and its long-term effects on reproductive health, endocrine function, inflammation, metabolism, cardiovascular health, body composition, lifestyle, and mental health in patients with PCOS. We offer recommendations for the post-covid-19 management of PCOS, emphasizing the necessity of a comprehensive, multidisciplinary approach to patient care. Furthermore, we discuss prospective research directions, highlighting the significance of continued investigations and clinical trials to evaluate treatment approaches for long COVID and its ramifications in individuals with PCOS.

show abstract

Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism

Quagliariello,

Canale,

Bisceglia

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Cardiovascular disease and cancer are the two leading causes of morbidity and mortality in the world. The emerging field of cardio-oncology described several shared risk factors that predispose patients to both cardiovascular disease and cancer. Post-acute COVID-19 syndrome is a chronic condition that occurs in many patients who have experienced a SARS-CoV-2 infection, mainly based on chronic fatigue, sedentary lifestyle, cramps, breathing difficulties, and reduced lung performance. Post-acute COVID-19 exposes patients to increased visceral adiposity, insulin resistance, myosteatosis, and white adipose tissue content (surrounded by M1 macrophages and characterized by a Th1/Th17 phenotype), which increases the risk of cardiovascular mortality and cancer recurrence. In this review, the main metabolic affections of post-acute COVID-19 syndrome in cancer patients at low and high risk of cardiomyopathies will be summarized. Furthermore, several non-pharmacological strategies aimed at reducing atherosclerotic and cardiac risk will be provided, especially through anti-inflammatory nutrition with a low insulin and glycemic index, appropriate physical activity, and immune-modulating bioactivities able to reduce visceral obesity and myosteatosis, improving insulin-related signaling and myocardial metabolism.

show abstract

SARS-CoV-2 Infection Alters the Phenotype and Gene Expression of Adipocytes

Cited by 3 publications

References 50 publications

FABP4 as a Therapeutic Host Target Controlling SARS-CoV2 Infection

FABP4 as a Therapeutic Host Target Controlling SARS-CoV2 Infection

COVID-19 and persistent symptoms: implications for polycystic ovary syndrome and its management

Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism

Contact Info

Product

Resources

About